Related Experiment Videos
Plasma fibronectin in idiopathic myelofibrosis and related chronic myeloproliferative disorders
1Department of Medicine, Gentofte University Hospital, Hellerup/Copenhagen, Denmark.
Abstract:
Plasma fibronectin concentrations were measured in 49 patients with chronic myeloproliferative disorders and compared to sex- and age-matched controls. A significantly lower plasma fibronectin concentration was observed in patients with idiopathic myelofibrosis as compared with the control group (p less than 0.01). In addition, plasma fibronectin concentrations in myelofibrosis patients differed significantly, when compared with patients with polycythaemia vera (p less than 0.01), whereas no significant difference was found between myelofibrosis patients and those with a transitional myeloproliferative disorder or chronic myelogenous leukaemia (p greater than 0.05). An inverse relationship was demonstrated between plasma fibronectin and spleen size, the lowest plasma fibronectin levels being found in patients with large spleens. It is supposed that low plasma fibronectin concentrations in splenomegalic patients may be due to enhanced consumption of the opsonin in the expanded splenic mononuclear-macrophage system.
Insights
Patients with idiopathic myelofibrosis have lower plasma fibronectin levels, especially those with larger spleens. This may indicate increased consumption in the spleen's immune system.
Area of Science:
- Hematology
- Biochemistry
Background:
- Chronic myeloproliferative disorders (MPDs) are a group of conditions affecting blood cell production.
- Plasma fibronectin, an important protein, plays a role in immune function and tissue repair.
Purpose of the Study:
- To investigate plasma fibronectin concentrations in patients with MPDs.
- To compare fibronectin levels between different MPD subtypes and healthy controls.
- To explore the relationship between fibronectin levels and clinical parameters like spleen size.
Main Methods:
- Measured plasma fibronectin concentrations in 49 patients with MPDs.
- Compared patient groups to sex- and age-matched controls.
- Analyzed fibronectin levels in relation to MPD subtypes (idiopathic myelofibrosis, polycythaemia vera, transitional myeloproliferative disorder, chronic myelogenous leukaemia) and spleen size.
Main Results:
- Significantly lower plasma fibronectin was observed in idiopathic myelofibrosis patients compared to controls (p < 0.01).
- Myelofibrosis patients showed significantly different fibronectin levels compared to polycythaemia vera patients (p < 0.01).
- No significant difference in fibronectin was found between myelofibrosis and transitional myeloproliferative disorder or chronic myelogenous leukaemia patients (p > 0.05).
- An inverse relationship existed between plasma fibronectin and spleen size, with lowest levels in patients having large spleens.
Conclusions:
- Idiopathic myelofibrosis is associated with reduced plasma fibronectin concentrations.
- Low fibronectin levels in splenomegalic patients may result from increased consumption within the splenic mononuclear-macrophage system.
- Plasma fibronectin may serve as a potential biomarker in certain myeloproliferative disorders.